Bristol-Myers Squibb to partner with QIMR Berghofer Medical Research Institute

Bristol-Myers Squibb has announced an immuno-oncology-focused partnership with Australia's QIMR Berghofer Medical Research Institute.

The research collaboration and license agreement will focus on the discovery of novel therapeutic antibodies against an undisclosed immuno-oncology target, leveraging the expertise and knowledge of both organisations.

A world-leading translational research institute, the QIMR Berghofer Medical Research Institute's work is focused on cancer, infectious diseases, mental health and a range of complex disorders.

Under the terms of the deal, Bristol-Myers Squibb will be solely responsible for the clinical development and commercialisation of antibodies discovered through the collaboration.

Dr Carl Decicco, head of discovery for Bristol-Myers Squibb's research and development division, said: "We are excited to work with QIMR Berghofer Medical Research Institute, a partner that brings significant experience and expertise in cancer research."

The company has identified immuno-oncology as a promising new avenue for delivering long-term survival and a positive quality of life for patients with cancer.